Our finding that suppression of neuronal NF-κB activity with IκB-SR alleviated proteinopathies and behavioral phenotypes in three mouse models of ALS or FTLD suggests that the NF-κB pathway in neurons constitutes a promising therapeutic target. Here, NFKB1 is linked to amyotrophic lateral sclerosis.